Acute tumor lysis syndrome in non-Hodgkin lymphoma induced by dexamethasone

Related Experiment Video

Updated: Oct 23, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

K Dhingra1, S R Newcom

  • 1Grady Memorial Hospital, Emory University School of Medicine, Atlanta, GA 30303.

American Journal of Hematology
|October 1, 1988
PubMed

Abstract:

Acute tumor lysis syndrome developed in a 30-year-old man with non-Hodgkin lymphoma after dexamethasone administration. To the best of our knowledge, this case is the first one reported following single agent corticosteroid treatment.

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Related Experiment Videos

Last Updated: Oct 23, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Related Concept Videos

Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...

Articles linked to this work by shared authors, journal, and citation graph.

Effectiveness of Azadirachta indica (neem) mouthrinse in plaque and gingivitis control: a systematic review.

International journal of dental hygiene·2016

Aloe vera herbal dentifrices for plaque and gingivitis control: a systematic review.

Oral diseases·2013

Methodological issues in randomized trials assessing probiotics for periodontal treatment.

Journal of periodontal research·2011

P53 alterations show significant correlation with gene amplification and s-phase index in breast-cancer.

International journal of oncology·2011

Management of gingival inflammation in orthodontic patients with ozonated water irrigation--a pilot study.

International journal of dental hygiene·2011

Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer.

Cancer investigation·2001

Clinical Experience of Iptacopan in Paroxysmal Nocturnal Hemoglobinuria.

American journal of hematology·2026

Integrated Multi-Omic Characterization of Hexokinase-1 Deficiency in Red Blood Cells Reveals Altered Redox Homeostasis, Membrane Remodeling, and Features of Incomplete Erythroid Maturation.

American journal of hematology·2026

Prognostic Impact of FLT3-ITD Allelic Ratio in AML Patients Treated With High-Dose Anthracycline and a FLT3 Inhibitor.

American journal of hematology·2026

Circulating Biomarkers Associated With Hereditary Hemorrhagic Telangiectasia Sensitive to ALK1 Modulation.

American journal of hematology·2026

New Drugs in Myelofibrosis: Incremental Progress in Symptom Management Without Disease Modification.

American journal of hematology·2026

Outcomes of Patients With AL Amyloidosis and End-Stage Renal Disease After Initiation of Therapy.

American journal of hematology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us